Background: Matrix metalloproteinase (MMP)-9 has been implicated in the development of pleural effusions. Objectives: The aim of this study was to assess the expression of MMP-9 in pleural effusions of tuberculosis, lung cancer and transudates. Methods: Ninety-one patients (37 tuberculous pleural effusions, 42 malignant pleural effusions of lung cancer and 12 transudates) were included. Concentrations of pleural fluid MMP-9 and tissue inhibitors of matrix metalloproteinase (TIMP)-1 were determined by immunoassay. We also investigated the cellular localization of MMP-9 and TIMP-1 by reverse-transcriptase polymerase chain reaction on lymphocytes from pleural effusions and by immunohistochemical analysis of pleural tissues. Results: Pleural fluid MMP-9 levels, MMP-9/total protein and MMP-9/TIMP-1 ratios were significantly higher in tuberculous pleural effusions, whilst TIMP-1 levels were similar in the three groups. MMP-9 levels positively correlated with TIMP-1 and lactate dehydrogenase levels, and negatively with pH and glucose levels in pleural effusions. MMP-9 mRNA expression in lymphocytes tended to be higher in malignant pleural effusions of lung cancer than in the other groups without reaching statistical significance. The strongest immunoreactivity for MMP-9 was observed in epithelioid cells of tuberculous pleural tissues. Much lower levels of MMP-9 expression were found in tumor cells of pleural tissues. Conclusions: MMP-9 is increased in tuberculous pleural effusions compared with transudates and malignant pleural effusions of lung cancer and is produced predominantly by epithelioid cells in the granulomas of tuberculous pleural tissues.

Keywords:
Matrix metalloproteinase-9, Tissue inhibitors of matrix metalloproteinase-1, Tuberculous pleural effusion, Malignant pleural effusion, Lung cancer
1.
Nagase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 1999;274:21491–21494.
2.
Baker AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719–3727.
3.
Stetler-Stevenson WG: Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996;148:1345–1350.
4.
Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145–2154.
5.
Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J: Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998;75:780–786.
6.
Hurewitz AN, Zucker S, Mancuso P, Wu CL, Dimassimo B, Lysik RM, Moutsiakis D: Human pleural effusions are rich in matrix metalloproteinases. Chest 1992;102:1808–1814.
7.
Eickelberg O, Sommerfeld CO, Wyser C, Tamm M, Reichenberger F, Bardin PG, Soler M, Roth M, Perruchoud AP: MMP and TIMP expression pattern in pleural effusions of different origins. Am J Respir Crit Care Med 1997;156:1987–1992.
8.
Gordon S, Cohn ZA: Bacille Calmette-Guérin infection in the mouse. Regulation of macrophage plasminogen activator by T lymphocytes and specific antigen. J Exp Med 1978;147:1175–1188.
9.
Gordon S, Todd J, Cohn ZA: In vitro synthesis and secretion of lysozyme by mononuclear phagocytes. J Exp Med 1974;139:1228–1248.
10.
Quiding-Jarbrink M, Smith DA, Bancroft GJ: Production of matrix metalloproteinases in response to mycobacterial infection. Infect Immun 2001;69:5661–5670.
11.
Friedland JS, Shaw TC, Price NM, Dayer JM: Differential regulation of MMP-1/9 and TIMP-1 secretion in human monocytic cells in response to Mycobacterium tuberculosis. Matrix Biol 2002;21:103–110.
12.
Rivera-Marrero CA, Schuyler W, Roser S, Ritzenthaler JD, Newburn SA, Roman J: M. tuberculosis induction of matrix metalloproteinase-9: The role of mannose and receptor-mediated mechanisms. Am J Physiol Lung Cell Mol Physiol 2002;282:L546–L555.
13.
Rivera-Marrero CA, Schuyler W, Roser S, Roman J: Induction of MMP-9 mediated gelatinolytic activity in human monocytic cells by cell wall components of Mycobacterium tuberculosis. Microb Pathog 2000;29:231–244.
14.
Hoheisel G, Sack U, Hui DS, Huse K, Chan KS, Chan KK, Hartwig K, Schuster E, Scholz GH, Schauer J: Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis. Tuberculosis (Edinb) 2001;81:203–209.
15.
Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43(suppl):S42–S51.
16.
Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ: Metalloproteinases in tumor progression: The contribution of MMP-9. Invasion Metastasis 1994;14:246–258.
17.
Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS: Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 2000;190:150–156.
18.
Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, Baba M, Shiba M: Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999;5:149–153.
19.
Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S, Kawai T: Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer 2002;35:249–255.
20.
Marshall BC, Santana A, Xu QP, Petersen MJ, Campbell EJ, Hoidal JR, Welgus HG: Metalloproteinases and tissue inhibitor of metalloproteinases in mesothelial cells. Cellular differentiation influences expression. J Clin Invest 1993;91:1792–1799.
21.
Goetzl EJ, Banda MJ, Leppert D: Matrix metalloproteinases in immunity. J Immunol 1996;156:1–4.
22.
Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW, Stephenson TJ, Rees RC: Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 1997;158:2327–2333.
23.
Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr: Pleural effusions: The diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507–513.
24.
Alexandrakis MG, Kyriakou D, Alexandraki R, Pappa KA, Antonakis N, Bouros D: Pleural interleukin-1 beta in differentiating transudates and exudates: Comparative analysis with other biochemical parameters. Respiration 2002;69:201–206.
25.
Tahhan M, Ugurman F, Gozu A, Akkalyoncu B, Samurkasoglu B: Tumour necrosis factor-alpha in comparison to adenosine deaminase in tuberculous pleuritis. Respiration 2003;70:270–274.
26.
Aoe K, Hiraki A, Murakami T, Eda R, Maeda T, Sugi K, Takeyama H: Diagnostic significance of interferon-gamma in tuberculous pleural effusions. Chest 2003;123:740–744.
27.
Atanackovic D, Block A, de Weerth A, Faltz C, Hossfeld DK, Hegewisch-Becker S: Characterization of effusion-infiltrating T cells: Benign versus malignant effusions. Clin Cancer Res 2004;10:2600–2608.
28.
Leber TM, Balkwill FR: Zymography: A single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem 1997;249:24–28.
29.
Yao PM, Maitre B, Delacourt C, Buhler JM, Harf A, Lafuma C: Divergent regulation of 92-kDa gelatinase and TIMP-1 by HBECs in response to IL-1beta and TNF-alpha. Am J Physiol 1997;273:L866–L874.
30.
Ara T, Kusafuka T, Inoue M, Kuroda S, Fukuzawa M, Okada A: Determination of imbalance between MMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progression. J Pediatr Surg 2000;35:432–437.
31.
Hurewitz AN, Wu CL, Mancuso P, Zucker S: Tetracycline and doxycycline inhibit pleural fluid metalloproteinases. A possible mechanism for chemical pleurodesis. Chest 1993;103:1113–1117.
32.
Saunders BM, Frank AA, Orme IM: Granuloma formation is required to contain bacillus growth and delay mortality in mice chronically infected with Mycobacterium tuberculosis. Immunology 1999;98:324–328.
33.
Smith D, Hansch H, Bancroft G, Ehlers S: T-cell-independent granuloma formation in response to Mycobacterium avium: Role of tumour necrosis factor-alpha and interferon-gamma. Immunology 1997;92:413–421.
34.
Orme IM, Cooper AM: Cytokine/chemokine cascades in immunity to tuberculosis. Immunol Today 1999;20:307–312.
35.
Tsuda T, Dannenberg AM Jr, Ando M, Rojas-Espinosa O, Shima K: Enzymes in tuberculous lesions hydrolyzing protein, hyaluronic acid and chondroitin sulfate: A study of isolated macrophages and developing and healing rabbit BCG lesions with substrate film techniques – The shift of enzyme pH optima towards neutrality in ‘intact’ cells and tissues. J Reticuloendothel Soc 1974;16:220–231.
36.
Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z: Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuberc Lung Dis 2002;6:713–719.
37.
Light RW: Clinical practice. Pleural effusion. N Engl J Med 2002;346:1971–1977.
38.
Saren P, Welgus HG, Kovanen PT: TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996;157:4159–4165.
39.
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729–733.
40.
Leib SL, Leppert D, Clements J, Tauber MG: Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun 2000;68:615–620.
41.
Aleman C, Alegre J, Segura RM, Armadans L, Surinach JM, Varela E, Soriano T, Recio J, Fernandez De Sevilla T: Polymorphonuclear elastase in the early diagnosis of complicated pyogenic pleural effusions. Respiration 2003;70:462–467.
42.
Good JT Jr, Taryle DA, Sahn SA: The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis 1985;131:737–741.
43.
Heffner JE, Nietert PJ, Barbieri C: Pleural fluid pH as a predictor of pleurodesis failure: Analysis of primary data. Chest 2000;117:87–95.
44.
Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K, Chamberlain D, Shepherd FA: Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999;17:1802–1808.
45.
Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE: Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992;66:1188–1194.
46.
Price NM, Farrar J, Tran TT, Nguyen TH, Tran TH, Friedland JS: Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J Immunol 2001;166:4223–4230.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.